Clinical Trials Search
A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 using the Intra-patient Escalation Dosing Regimen in Patients with Advanced Uveal Melanoma
This research study is investigating a drug (that is called IMCgp100) in participants with advanced uveal melanoma. This research study will test the study drug to assess the safety and tolerability of IMCgp100 and to see if IMCgp100 can make tumors stop growing (or shrink). Participants will receive a lower dose on the first two weeks and in the third week and beyond, participants will receive a higher dose of the study drug. The research study will look at how people's bodies respond to the study drug and what happens to the study drug as it moves through people's bodies.
Phase II Dose Expansion: The primary objective is to estimate the objective response rate by independent central review based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) in patients with advanced UM who are treated with the RP2D of IMCgp100 in the RP2D-IE